2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1129

Development and Validation Of a Rapid Knee Cartilage Quantification Method
Abstract Number: 1982

Development and Validation Of Medication Assessment Tools Specific For Rheumatoid Arthritis
Abstract Number: 289

Development and Validation Of The Cutoff Values For Disease Activity States Of The Three-Item Version Of The Juvenile Arthritis Disease Activity Score
Abstract Number: 2836

Development of a Health Index in Patients With Ankylosing Spondylitis (ASAS HI) – Final Result of a Global Initiative Based On the International Classification of Functioning, Disability and Health (ICF) Guided By Assesment of Spondyloarthritis International Society (ASAS)
Abstract Number: 497

Development Of a Novel Bispecific Therapeutic For Arthritic Diseases
Abstract Number: 977

Development Of a Tool To Assess Internal Medicine Residents’ Confidence In Their Musculoskeletal Examination Skills
Abstract Number: 1288

Development Of Antibodies Specific For Carbamylated Protein Precedes Disease Onset In Mice With Collagen-Induced Arthritis
Abstract Number: 2620

Development Of De Novo Major Involvement During The Follow-Up In Behçet’s Disease
Abstract Number: 1028

Development Of Patient-Reported Outcomes Measurement Information System (PROMIS®) Gastrointestinal (GI) Symptoms Item Bank
Abstract Number: 1699

Development Of Systemic Lupus Erythamatosus Among “Possible Systemic Lupus Erythamatosus ” Patients Seen In Consultation: Long-Term Follow-Up
Abstract Number: 2212

Development Of Tools To Facilitate Shared Decision Making About Medications For Juvenile Idiopathic Arthritis – A Project Of The Pediatric Rheumatology Care and Outcomes Improvement Network
Abstract Number: 2116

Diabetes: A Risk Factor For Poor Function Outcome After Total Knee Arthroplasty
Abstract Number: 2244

Diagnostic Accuracy Of Anti-Ccp Testing For Detecting Prevalent Rheumatoid Arthritis: Results From Screening a Population Based Cohort
Abstract Number: 909

Diagnostic Autoantibody Signatures Of Rheumatoid Arthritis Patients Identified With a Bead-Based Assay Approach
Abstract Number: 309

Diagnostic Delay Of Even More Than 6 Months Contributes To Poor Radiographic and Functional Outcome In Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].